The encouraging outcomes of the belimumab trials are likely to represent a true landmark in the quest to develop a more-targeted therapy for SLE. A cautionary note should be struck, however, when ...

Again, these changes support the positive effects of this drug on biologic activity and autoimmunity in SLE. The conclusions from the analysis of this trial were that belimumab offers a sustained ...

Several treatments that target B cells have, therefore, been investigated in patients with SLE. Furie et al. now report favorable results for their phase I trial of belimumab—a fully human ...

The time to first flare in active disease was delayed in both belimumab-treated groups of patients. Overall, the number of patients with severe SLE flare was reduced in the belimumab 1- and 10-mg ...

Belimumab combined with SOC was successful for inducing remission among patients with SLE, including those with LN.

The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...

In a new study, researchers examined four randomized controlled trials of belimumab (Benlysta®) to gain a better understanding of systemic lupus erythematosus (SLE) active disease progression with the ...

Discontinued. Please note that following on from information provided to NICE by the company in January 2022, the appraisal was suspended from NICE’s work programme. As no further information has been ...